US FDA delays decision on Sarepta Therapeutics’ drug to treat muscular dystrophy
The company said that it was informed by FDA that it will require another three months to complete its New Drug Application (NDA) review for eteplirsen. Sarepta received
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.